Shuttle Pharmaceuticals (NASDAQ:SHPH) Releases Earnings Results

Shuttle Pharmaceuticals (NASDAQ:SHPH) announced its quarterly earnings results on Friday. The company reported ($0.43) earnings per share (EPS) for the quarter, FiscalAI reports.

Shuttle Pharmaceuticals Trading Up 4.0%

Shares of SHPH stock traded up $0.03 during midday trading on Friday, reaching $0.67. 454,298 shares of the stock were exchanged, compared to its average volume of 2,360,916. The company’s 50 day moving average is $0.85 and its two-hundred day moving average is $1.47. The firm has a market cap of $3.72 million, a PE ratio of -0.06 and a beta of 0.38. Shuttle Pharmaceuticals has a 1 year low of $0.50 and a 1 year high of $6.19.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, May 4th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Trading of Shuttle Pharmaceuticals

Several institutional investors have recently bought and sold shares of SHPH. Connective Capital Management LLC purchased a new stake in shares of Shuttle Pharmaceuticals during the 3rd quarter valued at about $357,000. Ikarian Capital LLC purchased a new position in Shuttle Pharmaceuticals during the fourth quarter valued at $124,000. Boothbay Fund Management LLC purchased a new position in Shuttle Pharmaceuticals during the fourth quarter valued at $37,000. Finally, Geode Capital Management LLC purchased a new position in Shuttle Pharmaceuticals during the fourth quarter valued at approximately $26,000. 4.58% of the stock is owned by hedge funds and other institutional investors.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .